✦ LIBER ✦

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults

✍ Scribed by Verdijk, Pauline; Rots, Nynke Y.; van Oijen, Monique G.C.T.; Oberste, M. Steven; Boog, Claire J.; Okayasu, Hiromasa; Sutter, Roland W.; Bakker, Wilfried A.M.

Book ID: 121244300
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 415 KB
Volume: 31
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2013.09.021

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a subvirion

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

✍ Rebecca C. Brady; John J. Treanor; Robert L. Atmar; Wendy A. Keitel; Robert Edel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Immunogenicity, reactogenicity, and safe

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

✍ Tinoco, Juan Carlos; Pavia-Ruz, Noris; Cruz-Valdez, Aurelio; Aranza Doniz, Carlo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 603 KB

Safety and immunogenicity of inactivated

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

✍ Wendy A. Keitel; Cornelia L. Dekker; ChrisAnna Mink; James D. Campbell; Kathryn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Phase I and II randomised trials of the

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults

✍ Terry M. Nolan; Peter C. Richmond; Maryanne V. Skeljo; Georgina Pearce; Gunter H 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 591 KB

Safety and immunogenicity of a CTL multi

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

✍ Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary A 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 611 KB

A phase I trial of a DNA plasmid-based v

A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and immunogenicity

✍ Liao, J.B.; Cecil, D.L.; Reichow, J.; Parker, S.; Higgins, D.; Childs, J.; Brous 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB